Brian Park, PharmD

Drug Information Specialist https://www.cancertherapyadvisor.com

Brian Park, PharmD, is a Drug Information Specialist at MPR. A graduate of the Ernest Mario School of Pharmacy, Rutgers University, Brian worked as a pharmacy manager at Stop & Shop Pharmacy for 8 years. He is a certified diabetes care pharmacist.

All articles by Brian Park, PharmD

Prostate Cancer

Overall Survival Data Added to Nubeqa Prescribing Information

Brian Park, PharmD

January 11, 2021

Nubeqa, an androgen receptor inhibitor, was approved for the treatment of patients with nmCRPC based on data from the placebo-controlled phase 3 ARAMIS trial.

Prostate Cancer

Orgovyx Now Available for Advanced Prostate Cancer

Brian Park, PharmD

January 7, 2021

Orgovyx is an oral nonpeptide gonadotropin-releasing hormone (GnRH) receptor antagonist.

Lung Cancer

Tiragolumab Gets Breakthrough Therapy Status for PD-L1-High NSCLC

Brian Park, PharmD

January 7, 2021

Tiragolumab is a monoclonal antibody that works by binding to TIGIT, a protein receptor on immune cells, and blocking its interaction with the poliovirus receptor.

Lung Cancer

Opdivo No Longer FDA-Approved for Small Cell Lung Cancer

Brian Park, PharmD

January 6, 2021

In 2018, the FDA granted accelerated approval to Opdivo for SCLC based on data from the phase 1/2 CheckMate -032 trial.

Lung Cancer

Lorlatinib Under Review for Previously Untreated ALK-Positive NSCLC

Brian Park, PharmD

January 5, 2021

The sNDA is supported by data from the phase 3 CROWN study comparing lorlatinib to Xalkori in 296 adults with advanced ALK-positive NSCLC.

Chronic Myeloid Leukemia

Iclusig Approved for Resistant or Intolerant Chronic-Phase CML

Brian Park, PharmD

December 28, 2020

The sNDA approval is based on efficacy and safety data from the open-label phase 2 OPTIC trial and 5-year data from the phase 2 PACE trial.

Lung Cancer

Tagrisso Approved as Adjuvant Therapy for Early-Stage EGFR-Mutant NSCLC

Brian Park, PharmD

December 28, 2020

The approval was based on data from the double-blind, placebo-controlled phase 3 ADAURA study.

Multiple Myeloma

Xpovio Multiple Myeloma Indication Expanded

Brian Park, PharmD

December 28, 2020

The approval was based on data from the BOSTON trial that assessed Xpovio in combination with bortezomib and dexamethasone in 402 adults with relapsed or refractory multiple myeloma who had received 1 to 3 prior therapies.

Endocrine Cancer